Hao Su, Yongguang Wei, Xiwen Liao, Guangzhi Zhu, Minhao Peng, Fang Fan, Tao Peng
{"title":"Interpretation of the updates of the chinese guidelines for the diagnosis and treatment of primary liver cancer (CNLC-2024 Edition)","authors":"Hao Su, Yongguang Wei, Xiwen Liao, Guangzhi Zhu, Minhao Peng, Fang Fan, Tao Peng","doi":"10.20517/2394-5079.2024.70","DOIUrl":null,"url":null,"abstract":"Additional randomized controlled studies and high-level evidence for the diagnosis and management of liver cancer patients have been published since the release of Diagnosis and Treatment of Primary Liver Cancer Guidelines (CNLC-2022 edition). The 2024 version algorithm was updated accordingly by the national expert committee for the standardization and homogenization of liver cancer diagnosis and treatment in China. In this review, with reference to the guidelines of the 2022 version, we interpreted the main update points of the 2024 version to facilitate the nationwide dissemination and implementation of the guidelines.","PeriodicalId":12959,"journal":{"name":"Hepatoma Research","volume":" 9","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatoma Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20517/2394-5079.2024.70","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Additional randomized controlled studies and high-level evidence for the diagnosis and management of liver cancer patients have been published since the release of Diagnosis and Treatment of Primary Liver Cancer Guidelines (CNLC-2022 edition). The 2024 version algorithm was updated accordingly by the national expert committee for the standardization and homogenization of liver cancer diagnosis and treatment in China. In this review, with reference to the guidelines of the 2022 version, we interpreted the main update points of the 2024 version to facilitate the nationwide dissemination and implementation of the guidelines.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
